• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Devyser Diagnostics

86.70 SEK

-2.80 %

Less than 1K followers

DVYSR

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.80 %
-3.56 %
+8.92 %
-24.08 %
-21.18 %
-24.21 %
+13.19 %
-
-2.58 %

Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.

Read more
Market cap
1.46B SEK
Turnover
957.47K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.7.
2026

Interim report Q2'26

3.11.
2026

Interim report Q3'26

16.2.
2027

Annual report '26

Regulatory press release5/22/2026, 6:30 AM

Devyser strengthens its executive management team – Niklas Axelsson appointed new CFO and Sabina Berlin transitions to a new role within the company

Devyser Diagnostics
Regulatory press release5/6/2026, 11:30 AM

Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 6 May 2026

Devyser Diagnostics
Devyser Diagnostics, Audiocast, Q1'26
Webcast4/27/2026, 9:00 AM

Devyser Diagnostics, Audiocast, Q1'26

Devyser Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release4/27/2026, 7:00 AM

Devyser Diagnostics AB publishes quarterly report for the period January to March 2026

Devyser Diagnostics
Press release4/22/2026, 7:00 AM

Invitation to audiocast for Devyser’s Q1 report 2026

Devyser Diagnostics
Press release4/7/2026, 5:50 AM

Devyser announces that Chief Commercial Officer will leave the company

Devyser Diagnostics
Regulatory press release4/1/2026, 8:15 AM

Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares

Devyser Diagnostics
Press release3/25/2026, 9:00 AM

Devyser publishes annual report for 2025

Devyser Diagnostics
Press release3/4/2026, 9:00 AM

Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing

Devyser Diagnostics
Press release2/16/2026, 9:56 AM

Redeye: Devyser (Q4 Interview): Redeye has interviewed CEO Jan Wahlström

Devyser Diagnostics
Press release2/13/2026, 12:03 PM

Redeye: Devyser Diagnostics (Q4 Review): Jaw-dropping EBIT margin

Devyser Diagnostics
Devyser Diagnostics, Audiocast, Q4'25
Webcast2/12/2026, 8:00 AM

Devyser Diagnostics, Audiocast, Q4'25

Devyser Diagnostics
Regulatory press release2/12/2026, 6:30 AM

Devyser Diagnostics AB publishes year-end report for January to December 2025

Devyser Diagnostics
Regulatory press release2/11/2026, 7:05 PM

Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market

Devyser Diagnostics
Press release2/3/2026, 9:00 AM

Invitation to presentation of Devyser’s Q4 2025 Interim Report

Devyser Diagnostics
Press release1/28/2026, 9:00 AM

Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products

Devyser Diagnostics
Press release12/15/2025, 8:30 AM

Devyser wins Norwegian tender for Devyser CFTR at Oslo University Hospital

Devyser Diagnostics
Press release12/8/2025, 8:30 AM

Devyser secures a four-year tender in France for Devyser Compact

Devyser Diagnostics
Press release12/4/2025, 8:30 AM

Health Canada grants IVD approval to Devyser’s NGS-based chimerism test, the first of its kind in Canada

Devyser Diagnostics
Regulatory press release11/28/2025, 2:00 PM

Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test

Devyser Diagnostics